International Journal of Medical and Pharmaceutical Research
2024, Volume-5, Issue-5 doi: 10.5281/zenodo.12787999
Original Research Article
Management of Splenic Injury Following Blunt Trauma Abdomen
Published
Oct. 29, 2024
Abstract

Introduction: Blunt splenic trauma is a common clinical scenario, and its management has evolved significantly with the introduction of non-operative management (NOM). This prospective observational study aimed to evaluate the parameters that determine the choice of treatment and to compare the outcomes of NOM and surgical management.Materials and Methods:This study included 30 patients with blunt splenic trauma over a one-year period. Patients were divided into non-operative (n=12, 40%) and operative (n=18, 60%) management groups based on their clinical and hemodynamic status. Results: The non-operative management group had significantly higher systolic blood pressure (130 mmHg vs. 96 mmHg, p<0.001), lower heart rate (90 bpm vs. 110 bpm, p=0.002), and higher hemoglobin levels (11 g/dL vs. 9.75 g/dL, p=0.003) compared to the operative group. The non-operative group had a lower median transfusion requirement (0.3 units vs. 3 units, p=0.004) but a longer median hospital stay (15.9 days vs. 9.4 days, p=0.029). The success rate of non-operative management was 83.3% (10 out of 12 patients). Conclusion: Non-operative management is a safe and effective approach in the majority of patients with blunt splenic trauma, provided that the patient is hemodynamically stable. The clinical and hemodynamic parameters at admission are crucial determinants in the selection of the appropriate management approach.

Recommended Articles
Loading Image...
Volume-5, Issue-5
Citations
1012 Views
253 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved